trial

Deep Brain Stimulation for Psychosis

NCTId NCT06257056
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 10 (estimated)
Sponsored by Bradley Lega
Primary completion 2027-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
10 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
None
Start
2024-04-03
Primary completion
2027-04
Eligibility
ALL · 22 Years · 70 Years

Interventions & indications

Drugs
Abbott Laboratories Infinity™ implantable deep brain stimulation system

Sponsors

Bradley LegaLead Sponsor

Investigators

4
Bradley Lega, M.D.Principal Investigator
David J. Miklowitz, Ph.D.Principal Investigator
Nader Pouratian, M.D.Principal Investigator
Carol A. Tamminga, M.D.Principal Investigator

Sites

1 total
Dallas, United States

Facts & assertions

4 sourced
Enrollment
10
Phase
NA
Primary Completion Date
2027-04
Status
RECRUITING
relationships
The graph out of here
drug
Abbott Laboratories Infinity™ implantable deep brain stimulation system
drug
lead_sponsor
Bradley Lega
company
indication
Treatment-refractory Schizophrenia
indication
Schizophrenia, Treatment-Resistant
indication
Schizophrenia
indication
investigator
Bradley Lega, M.D.
person
David J. Miklowitz, Ph.D.
person
Nader Pouratian, M.D.
person
Carol A. Tamminga, M.D.
person